# US 2019/0172582 A1 · Methods and systems for determining somatic mutation clonality

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0172582 A1
- Document ID: US20190172582A1
- Status: Published application
- Kind: A1
- Application number: 16/208,290
- Filed: 2018-12-03
- Published: 2019-06-06
- Earliest claimed: 2017-12-01
- Assignees: Illumina, Inc.
- Applicants: Illumina, Inc.
- Inventors: Vitor Ferreira Onuchic; Kristina M. Kruglyak
- Web page: https://patentgrep.com/patent/US20190172582A1

## CPC

- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G06F 17/153: {Multidimensional correlation or convolution}
- G16B 20/10: Ploidy or copy number detection
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G06F: ELECTRIC DIGITAL DATA PROCESSING (computer systems based on specific computational models G06N)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Computer implemented methods and computer systems are provided for estimating cancer cell fractions indicating proportions of cancer cells carrying one or more mutations of interest using one or more nucleic acid samples from a subject. The methods and systems provided herein implement processes that use a variational Bayesian mixture model to cluster initial cancer cell fractions and obtain the one or more final cancer cell fractions, the initial cancer cell fractions accounting for cancer purity and copy numbers. The disclosed methods and systems improve accuracy, validity, and reliability of tests for cancer clonality, and save time, materials, cost, and computer resources required for the tests, which can help design more affective cancer treatments.

## Claims

### Claim 1

A method implemented using a computer system comprising one or more processors and system memory, the method comprising:
(a) receiving, by the one or more processors, genomic sequence data obtained by sequencing nucleic acids in at least one test sample from a subject, wherein the nucleic acids are from one or more subclones of cancer cells;
(b) determining a plurality of somatic mutation variants in the genomic sequence data;
(c) calculating, for each somatic mutation variant and by the one or more processors, an initial cancer cell fraction (iCCF) using a VAF, wherein a cancer cell fraction is a fraction of cancer cells having the somatic mutation variant among all cancer cells, and wherein the VAF is an allele frequency of the somatic mutation variant, thereby obtaining a plurality of iCCFs for the plurality of somatic mutation variants;
(d) clustering, by the one or more processors, the plurality of iCCFs for the plurality of somatic mutation variants, thereby obtaining one or more clusters of iCCFs, each cluster corresponding to variants present in a same subclone of the one or more subclones; and
(e) determining, by the one or more processors, one or more final cancer cell fractions (fCCFs) for one or more somatic mutations of the plurality of somatic mutations using iCCFs of the one or more clusters.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
aligning sequence reads of the genomic sequence data to a reference genome to provide sequence tags, wherein the reference genome comprises a plurality of loci, each locus of the plurality of loci harboring a somatic mutation of a plurality of somatic mutations; and
determining, for each locus of the plurality of loci, a coverage of the locus and a variant allele frequency (VAF) of the locus.

### Claim 3 (depends on 1)

The method of claim 1, further comprising estimating a tumor purity value (p) that is a fraction of tumor cells among all cells in the test sample using the genomic sequence data.

### Claim 4 (depends on 1)

The method of claim 1, further comprising estimating, for each locus of a plurality of loci, an average copy number of all alleles (N) at the locus for all cells in the test sample using the genomic sequence data.

### Claim 5 (depends on 4)

The method of claim 4, wherein the initial cancer cell fraction (iCCF) is calculated using VAF, p, and N.

### Claim at position 6

6-12. (canceled)

### Claim 13 (depends on 5)

The method of claim 5, wherein the iCCF is calculated based on (VAF*N)/p.

### Claim 14 (depends on 5)

The method of claim 5, wherein the iCCF is calculated using a copy number of the variant allele of the somatic mutation (n), as well as VAF, p, and N.

### Claim 15 (depends on 14)

The method of claim 14, wherein the iCCF is calculated based on (VAF*N)/(p*n).

### Claim 16 (depends on 15)

The method of claim 15, wherein the iCCF is calculating with an assumption that n is 1.

### Claim 17 (depends on 16)

The method of claim 16, wherein iCCF is calculated based on: (i) (VAF*N)/p when (VAF*N)/p is not larger than 1, and (ii) 1 when (VAF*N)/p is larger than 1.

### Claim 18 (depends on 1)

The method of claim 1, wherein the clustering comprises determining one or more posterior probabilities of a mutation belonging to the one or more clusters.

### Claim 19 (depends on 18)

The method of claim 18, wherein the one or more fCCFs are calculated using the one or more posterior probabilities and the plurality of iCCFs.

### Claim 20 (depends on 19)

The method of claim 19, wherein an fCCF for a mutation is calculated as a linear combination of a mean iCCF of somatic mutations in each cluster and a posterior probability of the mutation belonging to each cluster.

### Claim 21 (depends on 20)

The method of claim 20, wherein fCCFm for mutation m is calculated using the following formula:
fCCF
m
=
∑
k

(
iCCF
k
_
×
pr
m
,
k
)
wherein
iCCFk is the average iCCF of cluster k; and
prm,k is the probability that mutation m belongs to cluster k.

### Claim 22 (depends on 21)

The method of claim 21, wherein cluster k comprises a cluster of a highest probability for the mutation.

### Claim 23 (depends on 1)

The method of claim 1, wherein the clustering comprises using a mixture model to determine the one or more clusters.

### Claim 24 (depends on 23)

The method of claim 23, wherein the mixture model comprises a variational Bayesian mixture model.

### Claim 25 (depends on 23)

The method of claim 23, wherein the clustering comprises determining a number of subclones giving rise to the one or more clusters of iCCFs.

### Claim 26 (depends on 25)

The method of claim 25, wherein determining a subclone of the number of subclones comprises identifying a subset of the plurality of somatic sequence variants that cluster together based on estimated fractions of the subset all being within a predetermined range.

### Claim 27 (depends on 23)

The method of claim 23, wherein the mixture model comprises a mixture of two or more probability distributions of variant allele counts for two or more clusters.

### Claim 28 (depends on 27)

The method of claim 27, wherein each probability distribution of variant allele counts is selected from the group consisting of a binomial distribution, a beta distribution, a Gaussian distribution, and any combinations thereof.

### Claim 29 (depends on 28)

The method of claim 28, wherein each probability distribution of variant allele counts is a binomial distribution.

### Claim at position 24

30-31. (canceled)

### Claim 32 (depends on 28)

The method of claim 28, wherein iCCF of a mutation is modeled as beta random variable having a beta distribution for a cluster.

### Claim 33 (depends on 32)

The method of claim 32, wherein the at least one test sample comprises one sample, and a probability of a mutation belonging to a cluster is modeled as:
pr
m
,
k
=
Beta

(
f
;
u
k
,
v
k
)
=
Γ

(
u
k
+
v
k
)
Γ

(
u
k
)

Γ

(
v
k
)

f
u
k
-
1

(
1
-
f
)
v
k
-
1
wherein
prm,k is a probability that mutation m belongs to cluster k;
Beta(;) is a probability density function of a beta distribution for cluster k;
f is iCCF for mutation m;
Γ( ) is a gamma function; and
uk and vk are shape parameters of the beta distribution for cluster k.

### Claim 34 (depends on 32)

The method of claim 32, wherein the at least one test sample comprises two or more test samples, and a probability of a mutation belonging to a cluster is modeled as:
pr
m
,
k
=
p

(
f

u
k
,
v
k
)
=
Beta

(
f
;
u
k
,
v
k
)
=
∏
s
=
1
S


Beta

(
f
;
u
ks
,
v
ks
)
wherein uk and uv are the S-vectors whose sth components are uks and vks, respectively.

### Claim 35

(canceled)

### Claim 36 (depends on 1)

The method of claim 1, wherein one or more mutations of the plurality of somatic mutations overlap with one or more copy number variations (CNVs).

### Claim 37 (depends on 1)

The method of claim 1, wherein the method does not assume that all cancer cells are either affected by a CNV or not affected by the CNV.

### Claim 38 (depends on 37)

The method of claim 37, wherein the method does not assume that all cancer cells carrying a somatic mutation are either affected by a CNV or not affected by the CNV.

### Claim 39 (depends on 1)

The method of claim 1, wherein the clustering does not use Markov chain Monte Carlo (MCMC) methods.

### Claim 40 (depends on 1)

The method of claim 1, wherein the plurality of somatic mutations comprises a mutation selected from the group consisting of a single nucleotide variant (SNV), an indel, or a combination thereof.

### Claim 41

A system for characterizing cancer cells in at least one test sample comprising nucleic acids, the system comprising:
a sequencer for receiving nucleic acids from the test sample and providing nucleic acid sequence information of the test sample;
a processor; and
one or more computer-readable storage media having stored thereon instructions for execution on said processor to:
(a) receive genomic sequence data obtained by sequencing nucleic acids in at least one test sample from a subject, wherein the nucleic acids are from one or more subclones of cancer cells;
(b) determine a plurality of somatic mutation variants in the genomic sequence data;
(c) calculate, for each somatic mutation variant, an initial cancer cell fraction (iCCF) using a VAF, wherein a cancer cell fraction is a fraction of cancer cells having the somatic mutation variant among all cancer cells, and wherein the VAF is an allele frequency of the somatic mutation variant, thereby obtaining a plurality of iCCFs for the plurality of somatic mutation variants;
(d) cluster the plurality of iCCFs for the plurality of somatic mutation variants, thereby obtaining one or more clusters of iCCFs, each cluster corresponding to variants present in a same subclone of the one or more subclones; and
(e) determine one or more final cancer cell fractions (fCCFs) for one or more somatic mutations of the plurality of somatic mutations using iCCFs of the one or more clusters.

### Claim 42

(canceled)

### Claim 43

A computer program product comprising a non-transitory machine readable medium storing program code that, when executed by one or more processors of a computer system, causes the computer system to implement a method of characterizing cancer cells in at least one test sample comprising nucleic acids, said program code comprising:
(a) code for receiving genomic sequence data obtained by sequencing nucleic acids in at least one test sample from a subject, wherein the nucleic acids are from one or more subclones of cancer cells;
(b) code for determining a plurality of somatic mutation variants in the genomic sequence data;
(c) code for calculating, for each somatic mutation variant, an initial cancer cell fraction (iCCF) using a VAF, wherein a cancer cell fraction is a fraction of cancer cells having the somatic mutation variant among all cancer cells, and wherein the VAF is an allele frequency of the somatic mutation variant, thereby obtaining a plurality of iCCFs for the plurality of somatic mutation variants;
(d) code for clustering the plurality of iCCFs for the plurality of somatic mutation variants, thereby obtaining one or more clusters of iCCFs, each cluster corresponding to variants present in a same subclone of the one or more subclones; and
(e) code for determining one or more final cancer cell fractions (fCCFs) for one or more somatic mutations of the plurality of somatic mutations using iCCFs of the one or more clusters.
